Page last updated: 2024-10-31

methoxyamine and Anemia

methoxyamine has been researched along with Anemia in 1 studies

methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including antimetabolite and alkylating agents."2.78A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ( Adams, BJ; Anthony, SP; Figg, WD; Gerson, SL; Goldman, J; Gordon, MS; Leigh, BR; Liu, L; Mendelson, D; Ramanathan, RK; Rosen, LS; Spencer, S; Theuer, CP; Weiss, GJ; Xu, Y, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gordon, MS1
Rosen, LS1
Mendelson, D1
Ramanathan, RK1
Goldman, J1
Liu, L1
Xu, Y1
Gerson, SL1
Anthony, SP1
Figg, WD1
Spencer, S1
Adams, BJ1
Theuer, CP1
Leigh, BR1
Weiss, GJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable[NCT00692159]Phase 128 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for methoxyamine and Anemia

ArticleYear
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
    Investigational new drugs, 2013, Volume: 31, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2013